All In Biotech

Drug Trial Radar · NCT05561140

Resolution of Sickle Cell Leg Ulcers With Voxelotor

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Voxelotor for the Treatment of Leg Ulcers in Patients With Sickle Cell Disease

Last checked: Nov 20, 2026Latest source record: Jul 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

88

Actual

Start

May 30, 2022

Primary completion

Jun 26, 2024

Study completion Oct 22, 2024

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Sep 30, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase 3, multicenter, randomized, placebo-controlled study to evaluate the efficacy of voxelotor and standard of care for the treatment of leg ulcers in participants with sickle cell disease. The study is divided into a 5 study periods: Screening, Run-in, Randomized Treatment, Open-label Treatment, and Follow-up/End of Study (EOS). The study will be conducted in approximately 80 eligible participants at approximately 20 global clinical trial sites.

Conditions

  • Sickle Cell Disease
  • Leg Ulcers

Interventions

  • Voxelotor Oral TabletDrug

    Synthetic small molecule supplied as 500 mg tablets, administered Orally

  • PlaceboOther

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Achieved Resolution of the Target Ulcers by Week 12 in Randomized Treatment PeriodTime frame: Through Week 12 of randomized treatment period

Locations

23 sites in 3 countries. Site status is shown where the registry gives one.

  • Esho Empresa De Servicos Hospitalares S.A/ Hospital Samaritano Higienopolis

    São Paulo, Brazil

  • Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo

    São Paulo, Brazil

  • Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo

    São Paulo, Brazil

  • Complexo Hospitalar Universitário Professor Edgard Santos- Universidade Federal Da Bahia

    Salvador, Estado de Bahia, Brazil

  • Universidade Federal Da Bahia Hospital Universitário Professor Edgard Santos

    Salvador, Estado de Bahia, Brazil

  • Hospital São Rafael

    Salvador, Estado de Bahia, Brazil

  • Hospital das Clinicas da Universidade Federal de Minas Gerais

    Belo Horizonte, Minas Gerais, Brazil

  • Multihemo Servicos Medicos S/A

    Recife, Pernambuco, Brazil

  • Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo

    Cerqueira Cesar - Sao Paulo, São Paulo, Brazil

  • Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto da Universidade de Sao Paulo

    Ribeirão Preto, São Paulo, Brazil

  • KEMRI Kondele Children's Hospital within Jaramogi Oginga Odinga Teaching and Referral Hospital.

    Kisumu, Kenya

  • Gertrude's Children's Hospital

    Nairobi, Kenya

  • KEMRI-Centre for Respiratory Diseases Research-Nairobi

    Nairobi, Kenya

  • Strathmore University Medical Centre

    Nairobi, Kenya

  • KEMRI-CRDR, KEMRI Clinical Research Annex

    Siaya, Kenya

  • KEMRI Centre for Clinical Research Butere County Hospital

    Butere, Kakamega County, Kenya

  • Barau Dikko Teaching Hospital/Kaduna State University

    Kaduna, Nigeria

  • Aminu kano Teaching Hospital

    Kano, Nigeria

  • Lagos University Teaching Hospital

    Lagos, Nigeria

  • SYNLAB

    Gwagwalada, Abuja, Nigeria

  • University of Calabar Teaching Hospital

    Calabar, Cross River State, Nigeria

  • SYNLAB

    Abuja, Federal Capital Territory, Nigeria

  • University of Abuja Teaching Hospital

    Gwagwalada, Federal Capital Territory, Nigeria

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.